

AssayMax™ Human TFPI ELISA Kit

Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO 63301 T (636) 447-9175 F (636) 395-7419 www.assaypro.com

For any questions regarding troubleshooting or performing the assay, please contact our support team at support@assaypro.com.

Thank you for choosing Assaypro.

Assay Summary

Step 1. Add 50 μl of Standard or Sample per well. Incubate 2 hours.

Step 2. Wash, then add 50 μ l of Biotinylated Antibody per well. Incubate 1 hour.

Step 3. Wash, then add 50 μ l of SP Conjugate per well. Incubate 30 minutes.

Step 4. Wash, then add 50 μ l of Chromogen Substrate per well. Incubate 20 minutes.

Step 5. Add 50 μ l of Stop Solution per well. Read at 450 nm immediately.

Symbol Key



Consult instructions for use.

Assay Template

12								
11								
10								
6								
∞								
7								
9								
.c								
4								
ю								
2								
1								
	Ą	В	3	Q	3	Ŧ	9	I

AssayMax™ Human Tissue Factor Pathway Inhibitor (TFPI) ELISA Kit

Catalog No. ET1005-1
Sample insert for reference use only

Introduction

Tissue factor pathway inhibitor (TFPI) is an endogenous protease inhibitor that regulates the initiation of the extrinsic coagulation pathway by producing factor Xa-mediated feedback inhibition of the tissue factor/factor VIIa (TF/FVIIa) catalytic complex (1). TFPI has a negatively charged aminoterminus, three tandem Kunitz proteinase inhibitory domains, and a positively charged carboxy-terminus. The first Kunitz domain is the binding site for the TF/FVIIa complex, and the second domain is for factor Xa. The resultant quaternary complex of TFPI/FXa/TF/FVIIa lacks TF/FVIIa catalytic activity (2). The third Kunitz-type domain and the carboxy-terminus of TFPI mediate its binding to heparin and cell surfaces including the endothelium (3). TFPI is synthesized mainly by endothelial cells and is present in three pools in vivo: 10% in platelets, in endothelium associated with endothelial glycosaminoglycans, and in plasma circulating as free or lipoprotein associated forms (4). The plasma TFPI contains mostly 34 and 40 kDa forms, and the concentration is approximately 50 – 100 ng/ml (5-6). Measurement of TFPI could be important in thrombogenesis, atherosclerosis, and heparinization studies. Higher plasma levels of TFPI were found in older individuals, pregnant women, and patients with advanced cancer (7-9).

Principle of the Assay

The AssayMax™ Human Tissue Factor Pathway Inhibitor ELISA (Enzyme-Linked Immunosorbent Assay) Kit is designed for detection of TFPI in human plasma, serum, milk, and CSF samples. This assay employs a quantitative sandwich enzyme immunoassay technique that measures human TFPI in approximately 4 hours. A polyclonal antibody specific for human TFPI has been pre-coated onto a 96-well microplate with removable strips. TFPI in standards and samples is sandwiched by the immobilized antibody and a biotinylated polyclonal antibody specific for human TFPI, which is recognized by a streptavidin-peroxidase (SP) conjugate. All unbound material is washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

Caution and Warning

- This product is for Research Use Only and is not intended for use in diagnostic procedures.
- Prepare all reagents (diluent buffer, wash buffer, standard, biotinylated antibody, and SP conjugate) as instructed, prior to running the assay.
- Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this insert. However, the user should determine the optimal dilution factor.
- Spin down the SP conjugate vial and the biotinylated antibody vial before opening and using contents.
- The Stop Solution is an acidic solution.
- The kit should not be used beyond the expiration date.

Reagents

- Human TFPI Microplate: A 96-well polystyrene microplate (12 strips of 8 wells) coated with a polyclonal antibody against human TFPI.
- Sealing Tapes: Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- Human TFPI Standard: Human TFPI in a buffered protein base (3 ng, lyophilized, 2 vials).
- Biotinylated Human TFPI Antibody (50x): A 50-fold concentrated biotinylated polyclonal antibody against human TFPI (120 μl).
- MIX Diluent Concentrate (10x): A 10-fold concentrated buffered protein base (30 ml).
- Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- SP Conjugate (100x): A 100-fold concentrate (80 μl).
- Chromogen Substrate (1x): A stabilized peroxidase chromogen substrate tetramethylbenzidine (7 ml).
- **Stop Solution (1x):** A 0.5 N hydrochloric acid solution to stop the chromogen substrate reaction (11 ml).

Storage Condition

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store SP Conjugate and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.

 Store Standard at 2-8°C before reconstituting with Diluent and at -20°C after reconstituting with Diluent.

Other Supplies Required

- Microplate reader capable of measuring absorbance at 450 nm
- Pipettes (1-20 μl, 20-200 μl, 200-1000 μl, and multiple channel)
- Deionized or distilled reagent grade water

Sample Collection, Preparation, and Storage

- Plasma: Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 3000 x g for 10 minutes and collect plasma. A 40-fold sample dilution is suggested into MIX Diluent or within the range of 10x 80x; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles (EDTA or Heparin can also be used as an anticoagulant).
- **Serum:** Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 3000 x g for 10 minutes and remove serum. A 40-fold sample dilution is suggested into MIX Diluent or within the range of 10x 80x; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- **Milk:** Collect milk using sample tube. Centrifuge samples at 800 x g for 10 minutes. The sample is suggested for use at 1x; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- CSF: Collect cerebrospinal fluid (CSF) using sample pot. Centrifuge samples at 3000 x g for 10 minutes. The sample is suggested for use at 1x; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.

Applicable samples may also include biofluids, cell culture, and tissue homogenates. If necessary, user should determine optimal dilution factor depending on application needs.

Refer to Dilution Guidelines for further instruction.

	Guidelines for Dilutions of 100-fold or Greater (for reference only; please follow the insert for specific dilution suggested)				
	100x		10000x		
A)	4 μl sample: 396 μl buffer (100x) = 100-fold dilution Assuming the needed volume is less than or equal to 400 μl.	A) B)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) = 10000-fold dilution Assuming the needed volume is less than or equal to 400 μl.		
	1000x		100000x		
A) B)	4 μl sample : 396 μl buffer (100x) 24 μl of A : 216 μl buffer (10x) = 1000-fold dilution Assuming the needed volume is less than	A) B) C)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) 24 μl of B : 216 μl buffer (10x) = 100000-fold dilution		
	or equal to 240 μ l.		Assuming the needed volume is less than or equal to 240 μ l.		

Reagent Preparation

- Freshly dilute all reagents and bring all reagents to room temperature before use.
- MIX Diluent Concentrate (10x): Dilute the MIX Diluent Concentrate 10-fold with reagent grade water to produce a 1x solution. When diluting the concentrate, make sure to rinse the bottle thoroughly to extract any precipitates left in the bottle. Mix the 1x solution gently until the crystals have completely dissolved. Store for up to 30 days at 2-8°C.
- Human TFPI Standard: Reconstitute the Human TFPI Standard (3 ng) with 0.3 ml of MIX Diluent to generate a 10 ng/ml standard stock solution. Allow the vial to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting from the standard stock solution (10 ng/ml) 2-fold with equal volume of MIX Diluent to produce 5, 2.5, 1.25, 0.625, 0.313, and 0.156 ng/ml solutions. MIX Diluent serves as the zero standard (0 ng/ml). Any remaining stock solution should be stored at -20°C and used within 30 days. Avoid repeated freeze-thaw cycles.

Standard Point	Dilution	[TFPI] (ng/ml)
P1	1 part Standard (10 ng/ml)	10
P2	1 part P1 + 1 part MIX Diluent	5.0
Р3	1 part P2 + 1 part MIX Diluent	2.5
P4	1 part P3 + 1 part MIX Diluent	1.25
P5	1 part P4 + 1 part MIX Diluent	0.625
P6	1 part P5 + 1 part MIX Diluent	0.313
P7	1 part P6 + 1 part MIX Diluent	0.156
P8	MIX Diluent	0.0

- Biotinylated Human TFPI Antibody (50x): Spin down the antibody briefly and dilute the desired amount of the antibody 50-fold with MIX Diluent to produce a 1x solution. The undiluted antibody should be stored at -20°C.
- Wash Buffer Concentrate (20x): Dilute the Wash Buffer Concentrate 20fold with reagent grade water to produce a 1x solution. When diluting
 the concentrate, make sure to rinse the bottle thoroughly to extract any
 precipitates left in the bottle. Mix the 1x solution gently until the crystals
 have completely dissolved.
- SP Conjugate (100x): Spin down the SP Conjugate briefly and dilute the desired amount of the conjugate 100-fold with MIX Diluent to produce a 1x solution. The undiluted conjugate should be stored at -20°C.

Assay Procedure

- Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them immediately to the foil pouch with desiccants inside. Reseal the pouch securely to minimize exposure to water vapor and store in a vacuum desiccator.
- Add 50 µl of Human TFPI Standard or sample to each well. Gently tap
 plate to thoroughly coat the wells. Break any bubbles that may have
 formed. Cover wells with a sealing tape and incubate for 2 hours. Start
 the timer after the last addition.
- Wash the microplate manually or automatically using a microplate
 washer. Invert the plate and decant the contents; hit 4-5 times on
 absorbent material to completely remove the liquid. If washing
 manually, wash five times with 200 µl of Wash Buffer per well. Invert the
 plate each time and decant the contents; hit 4-5 times on absorbent
 material to completely remove the liquid. If using a microplate washer,

- wash six times with 300 µl of Wash Buffer per well; invert the plate and hit 4-5 times on absorbent material to completely remove the liquid.
- Add 50 µl of Biotinylated Human TFPI Antibody to each well. Gently tap
 plate to thoroughly coat the wells. Break any bubbles that may have
 formed. Cover wells with a sealing tape and incubate for 1 hour.
- Wash the microplate as described above.
- Add 50 µl of SP Conjugate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.
- Add 50 µl of Chromogen Substrate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Incubate in ambient light for 20 minutes or until the optimal blue color density develops.
- Add 50 μ l of Stop Solution to each well. The color will change from blue to yellow. Gently tap plate to ensure thorough mixing. Break any bubbles that may have formed.
- Read the absorbance on a microplate reader at a wavelength of 450 nm immediately. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections.
 Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

Data Analysis

- Calculate the mean value of the duplicate or triplicate readings for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance (OD) on the y-axis. The best fit line can be determined by regression analysis using log-log or four-parameter logistic curve fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.

Typical Data


The typical data is provided for reference only. Individual laboratory
means may vary from the values listed. Variations between laboratories
may be caused by technique differences.

Standard Point	ng/ml	OD	Average OD
D1	P1 10		2.157
ΓI	10	2.174	2.137
P2	5.0	1.715	1.721
12	5.0	1.727	1.721
P3	2.5	1.070	1.082
гэ	2.3	1.094	1.002
P4	1.25	0.652	0.646
F 4	0.640	0.640	0.040
P5	0.625	0.395	0.402
L D	0.625 0.409	0.409	0.402
P6	0.313	0.261	0.272
FU	0.515	0.283	0.272
P7	0.156	0.177	0.186
F /	0.130	0.195	0.180
P8	0.0	0.103	0.097
P8 U.U		0.091	0.037
Sample: Poo	oled Normal	0.688	0.722
Sodium Citrate	e Plasma (40x)	0.778	0.733

Standard Curve

• The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.

Human TFPI Standard Curve



Reference Value

- Normal human TFPI plasma and serum levels range from 47 73 ng/ml.
- Plasma and serum samples from healthy adults were tested (n=40). On average, human TFPI level was 63.2 ng/ml.

Sample	n	Average Value (ng/ml)
Pooled Normal Plasma	10	70.7
Normal Plasma	20	58.6
Pooled Normal Serum	10	60.3

Performance Characteristics

- This kit measures total TFPI concentration.
- The minimum detectable dose of human TFPI as calculated by 2SD from the mean of a zero standard was established to be 81 pg/ml.
- Intra-assay precision was determined by testing three plasma samples twenty times in one assay.
- Inter-assay precision was determined by testing three plasma samples in twenty assays.

	Intra-Assay Precision			Inter	-Assay Pred	ision
Sample	1	2	3	1	2	3
n	20	20	20	20	20	20
CV (%)	5.6%	5.1%	4.3%	10.2%	9.9%	9.6%
Average CV (%)		5.0%			9.9%	

Recovery

Standard Added Value	0.625 – 5 ng/ml
Recovery %	91 – 105%
Average Recovery %	98%

Linearity

• Plasma and serum samples were serially diluted to test for linearity.

Average Percentage of Expected Value (%)			
Sample Dilution	Plasma	Serum	
20x	93%	95%	
40x	101%	101%	
80x	104%	107%	

Cross-Reactivity

Species	Cross-Reactivity (%)
Canine	None
Bovine	None
Monkey	15%
Mouse	None
Rat	None
Swine	10%
Rabbit	None

Troubleshooting

Issue	Causes	Course of Action
	Use of improper components	Check the expiration date listed before use. Do not interchange components from different lots.
	Improper wash step	Check that the correct wash buffer is being used. Check that all wells are empty after aspiration. Check that the microplate washer is dispensing properly. If washing by pipette, check for proper pipetting technique.
cisio	Splashing of reagents while loading wells	Pipette properly in a controlled and careful manner.
Low Precision	Inconsistent volumes loaded into wells	 Pipette properly in a controlled and careful manner. Check pipette calibration. Check pipette for proper performance.
7	Insufficient mixing of reagent dilutions	 Thoroughly agitate the lyophilized components after reconstitution. Thoroughly mix dilutions.
	Improperly sealed microplate	Check the microplate pouch for proper sealing. Check that the microplate pouch has no punctures. Check that three desiccants are inside the microplate pouch prior to sealing.
gnal	Microplate was left unattended between steps	Each step of the procedure should be performed uninterrupted.
High Si	Omission of step Steps performed in incorrect order	Consult the provided procedure for complete list of steps. Consult the provided procedure for the correct order.
Unexpectedly Low or High Signal Intensity	Insufficient amount of reagents added to wells	Check pipette calibration. Check pipette for proper performance.
₽₽	Wash step was skipped	Consult the provided procedure for all wash steps.
tec	Improper wash buffer	 Check that the correct wash buffer is being used.
хрес	Improper reagent preparation	 Consult reagent preparation section for the correct dilutions of all reagents.
Unex	Insufficient or prolonged incubation periods	Consult the provided procedure for correct incubation time.

Deficient Standard Curve Fit	Non-optimal sample dilution	Sandwich ELISA: If samples generate OD values higher than the highest standard point (P1), dilute samples further and repeat the assay. Competitive ELISA: If samples generate OD values lower than the highest standard point (P1), dilute samples further and repeat the assay. User should determine the optimal dilution factor for samples.
nda	Contamination of reagents	 A new tip must be used for each addition of different samples or reagents during the assay procedure.
ıt Sta	Contents of wells evaporate	Verify that the sealing film is firmly in place before placing the assay in the incubator or at room temperature.
Deficien	Improper pipetting	Pipette properly in a controlled and careful manner. Check pipette calibration. Check pipette for proper performance.
	Insufficient mixing of reagent dilutions	Thoroughly agitate the lyophilized components after reconstitution. Thoroughly mix dilutions.

References

- (1) Broze GJ Jr. (1995) Annu Rev Med. 46:103.
- (2) Rapaport SI et al. (1990) Adv Exp Med Biol. 281:97.
- (3) Wesselschmidt RI et al. (1993) Blood Coag Fibrinol. 4:661.
- (4) Novotny WF et al. (1989) J Biol Chem. 264:18831.
- (5) Broze GJ et al. (1994) Blood Coag Fibrinol. 5:551.
- (6) Sandset PM et al. (1991) Haemostasis. 22:219.
- (7) Sandset PM et al. (1989) Haemostasis. 19:189.
- (8) Novotny WF et al. (1989) J Biol Chem. 264:18832.
- (9) Lindahl AK et al. (1989) Acta Chir Scand. 155:389.

Version 11.4R3